THALIA THERAPEUTICS PLC (THAT) — Investor Webinar

Investor webinar replay

Replay transcript excerpt

Good morning, ladies and gentlemen, and welcome to the Enfull Pharma PLC Investor Presentation. Throughout this recorded presentation, investors will be in listen only mode. Questions are encouraged. They can be submitted at any time via the Q and A tab that's situated on the right hand corner of your screen. Please just simply type in your questions and press send. The company may not be in a position to answer every question it receives during the meeting itself. However, the company can review all questions submitted today and we'll publish those responses where it's appropriate to do so on the Investor Meet company platform. Before we begin, we would just like to submit the following poll. And if you could give that your kind attention, I'm sure the company would be most grateful. And I would now like to hand you over to the team from Enfor Pharma PLC. Nigel, good morning, sir. Good morning, Jake, and thank you very much for the introduction. And and thank you everybody for joining us today. My name is Nigel Thierbold. I'm the chief executive of n four Pharma. And we're also joined today by Alastair Smith, who is a recently appointed non e exec director. And Alastair will give you a bit more of a background on himself as we go through. So without further ado, I'll I'll just walk through our investor presentation. I just wanna give you, first off, a little bit of an overview of n four. So, yeah, we see ourselves as a really exciting investment opportunity in what is a very differentiated and hugely successful and growing biotech market. And And we see, you know, significant upside potential for us as a business based on where we are today with our current share price. And what we're doing is we are developing proprietary gene delivery platform, which we call Nuvec...